Beyond Boundaries: The FDA’s Authority and Federal Preemption of State Mifepristone Regulations

This paper explores the intersection of federal preemption doctrine and state-level abortion restrictions, specifically focusing on the regulation of Mifepristone, a widely used abortion medication. I argue that state-imposed restrictions on Mifepristone are preempted by the Federal Food, Drug, and Cosmetic Act (FDCA), enforced by the FDA, based on an analysis of precedent federal court cases on preemption. The analysis delves into the complex regulatory landscape shaped by significant legal milestones, including the 2022 Dobbs v. Jackson Women's Health Organization decision, which has profoundly influenced state-level legislation on reproductive healthcare. Utilizing data from the Centers for Disease Prevention and Control's Abortion Surveillance System, the study categorizes states based on their Mifepristone restrictions and calculates the proportion of individuals compelled to seek abortion care outside their home states from 2012-2021. The findings highlight a marked increase in interstate travel for abortion services, particularly from states with stringent restrictions, underscoring the barriers these laws create against accessing safe and effective reproductive care. The paper contributes to the discourse on the legal clashes between state sovereignty and federal mandates, offering insights into how federal preemption could serve as a legal basis for challenging state restrictions that not only contravene federal law but also significantly hinder access to healthcare. This analysis is crucial for understanding the broader implications of legal and regulatory strategies on public health and civil liberties in the context of American federalism.